Rubicon Research Q1 FY27: Revenue up 51% to ₹534 Cr, PAT surges 96% to ₹85 Cr
Rubicon Research reported Q1 FY27 revenue of ₹534 crore, up 51% YoY, with PAT at ₹85 crore, up 96%. The Arinna acquisition contributed ₹12 crore to revenue. The company acquired a US manufacturing site for USD 2.9 million and revised its FY27 EBITDA margin guidance to 23%. Nitin Jajodia moves to Chief Commercial Officer; Rohit becomes CFO.
The significant growth in key financial metrics, strategic acquisitions (Arinna and US facility), positive guidance revision, and key management changes indicate a substantial impact on the company's future performance and investor outlook.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, exceeding expectations and revising EBITDA margin guidance upwards. Strategic acquisitions and facility approvals also contribute positively.
Rubicon Research Limited announced strong financial results for the first quarter of Fiscal Year 2026-27 (Q1 FY27), reporting a significant year-on-year revenue growth of 51% to ₹534 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) increased by 65% to ₹131 crore, and Profit After Tax (PAT) surged by over 95% to ₹85 crore.
The company's performance was bolstered by the recent acquisition of Arinna Lifesciences, which closed in April and contributed approximately ₹12 crore to the revenue with no material impact on EBITDA. Consolidated revenue from operations for the quarter stood at ₹5,343 million (₹534.3 crore), a 52% increase compared to the same quarter last year. Gross profit saw a robust growth of 46% to ₹3,543 million (₹354.3 crore).
Operating EBITDA for the quarter was ₹1,291 million (₹131 crore), a strong growth of 63.2% over the previous year, with operating EBITDA margins improving to 24.2% from 22.4% in Q1 FY26. PAT, after accounting for a one-off insurance claim, grew by 96% to ₹848 million (₹85 crore), resulting in an Earnings Per Share (EPS) of ₹5.08.
The company also highlighted strategic developments, including the acquisition of a manufacturing site in New Jersey, USA, for USD 2.9 million. This facility, with a positive USFDA inspection record, is expected to enhance supply chain capabilities and enable onshore manufacturing of specialty and high-value products. Additionally, the Pithampur facility received FDA approval following an inspection, with commercial operations expected to ramp up from Q1 CY2027.
Management has revised the EBITDA margin guidance for FY27 upwards to 23%, from the earlier 22%-23%, despite anticipated costs related to ESOPs, Arinna's integration, and new facilities. R&D expenditure remained a focus, with productivity measured at 5.5x based on Q1 FY27 figures, and the company is on track to meet its nine-quarter R&D spend guidance of ₹500 crore by Q1 FY28.
In a significant organizational update, Nitin Jajodia, the current CFO, will transition to the role of Chief Commercial Officer, and Rohit will join as the new CFO. This move is aimed at strengthening management bandwidth for the company's next phase of growth.
What to do with a filing like this
Rubicon Research Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rubicon Research Limited. Read the original for the full detail.